Nenad Tomasevic, Dren Bio CEO
Pfizer's hot start to the new year continues with licensing deal for mysterious biotech's solid tumor bispecifics
Pfizer has been quite busy as the new year kicked off, and Tuesday the Big Pharma struck yet another deal — this time with a little …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
